Krahasoni metodat

	Indeksi i Funksionit të Spondilitit Ankilozant të Bathit (BASFI)	Indeksi i Aktivitetit të Sëmundjes së Spondilitit Ankilozues (BASDAI)
Fusha	Reumatologji	Reumatologji
Familja	Process / pipeline	Process / pipeline
Viti i origjinës	1994	1994
Krijuesi	Calin et al.	Garrett et al.
Lloji	Patient-reported outcome (PRO)	Patient-reported outcome (PRO)
Burimi themelues	Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. The Journal of Rheumatology. 1994;21(12):2281-2285.	Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. 1994;21(12):2286-2291.
Emërtime të tjera	BASFI, BAS-FI	BASDAI, BAS-DAI
Të lidhura	4	4
Përmbledhja	The BASFI is a patient-reported outcome measure of functional disability in ankylosing spondylitis (AS), assessing physical limitations in 10 common daily activities. Introduced by Calin et al. in 1994, BASFI measures the impact of AS on quality of life and functional capacity, complementing BASDAI (disease activity). While BASDAI reflects inflammatory burden, BASFI reflects the consequences of inflammation and spinal damage on a patient's ability to perform daily tasks. BASFI is used alongside BASDAI in AS management to capture both disease activity and its functional impact.	The BASDAI is a patient-reported outcome measure of disease activity in ankylosing spondylitis (AS), a chronic inflammatory arthropathy affecting the spine and axial skeleton. Introduced by Garrett et al. in 1994, BASDAI uses six simple patient self-report items focused on the cardinal symptoms of AS: fatigue, spinal pain, peripheral joint involvement, and morning stiffness. As a PRO measure, BASDAI is practical for routine monitoring, responsive to treatment, and strongly associated with clinical outcomes and spinal damage progression, making it a cornerstone outcome in AS management and clinical trials.